About aktis oncology inc - AKTS
Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
AKTS At a Glance
Aktis Oncology, Inc.
17 Drydock Avenue
Boston, Massachusetts 02210
| Phone | 1-617-461-4023 | Revenue | 1.49M | |
| Industry | Pharmaceuticals: Major | Net Income | -43,980,000.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
AKTS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
AKTS Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | 0.006 |
AKTS Liquidity
| Current Ratio | 15.984 |
| Quick Ratio | 15.984 |
| Cash Ratio | 15.788 |
AKTS Profitability
| Gross Margin | -5.918 |
| Operating Margin | -3,500.336 |
| Pretax Margin | -2,957.633 |
| Net Margin | -2,957.633 |
| Return on Assets | -19.219 |
| Return on Equity | -25.178 |
| Return on Total Capital | -17.072 |
| Return on Invested Capital | -23.649 |
AKTS Capital Structure
| Total Debt to Total Equity | 4.89 |
| Total Debt to Total Capital | 4.662 |
| Total Debt to Total Assets | 3.626 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 4.159 |